Daniel B Soland - Net Worth and Insider Trading
Daniel B Soland Net Worth
The estimated net worth of Daniel B Soland is at least $268,605 dollars as of 2024-12-26. Daniel B Soland is the Director of ACADIA Pharmaceuticals Inc and owns about 10,000 shares of ACADIA Pharmaceuticals Inc (ACAD) stock worth over $173,700. Daniel B Soland is the Director of KalVista Pharmaceuticals Inc and owns about 10,000 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $88,300. Daniel B Soland is also the Director of DBV Technologies SA and owns about 2,000 shares of DBV Technologies SA (DBVT) stock worth over $5,960. Besides these, Daniel B Soland also holds Aceragen Inc (ACGN) . Details can be seen in Daniel B Soland's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Daniel B Soland has not made any transactions after 2023-08-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Daniel B Soland
Daniel B Soland Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Daniel B Soland owns 4 companies in total, including KalVista Pharmaceuticals Inc (KALV) , ACADIA Pharmaceuticals Inc (ACAD) , and Aceragen Inc (ACGN) among others .
Click here to see the complete history of Daniel B Soland’s form 4 insider trades.
Insider Ownership Summary of Daniel B Soland
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KALV | KalVista Pharmaceuticals Inc | 2020-10-01 | director |
| ACAD | ACADIA Pharmaceuticals Inc | 2019-06-26 | director |
| ACGN | Aceragen Inc | 2021-03-05 | Chief Operating Officer |
 | | 2023-08-01 | director |
Daniel B Soland Latest Holdings Summary
Daniel B Soland currently owns a total of 4 stocks. Among these stocks, Daniel B Soland owns 10,000 shares of ACADIA Pharmaceuticals Inc (ACAD) as of March 2, 2018, with a value of $173,700 and a weighting of 64.67%. Daniel B Soland owns 10,000 shares of KalVista Pharmaceuticals Inc (KALV) as of September 27, 2019, with a value of $88,300 and a weighting of 32.87%. Daniel B Soland also owns 2,000 shares of DBV Technologies SA (DBVT) as of August 1, 2023, with a value of $5,960 and a weighting of 2.22%. The other 1 stocks Aceragen Inc (ACGN) have a combined weighting of 0.24% among all his current holdings.
Latest Holdings of Daniel B Soland
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc | 2018-03-02 | 10,000 | 17.37 | 173,700 |
| KALV | KalVista Pharmaceuticals Inc | 2019-09-27 | 10,000 | 8.83 | 88,300 |
| DBVT | DBV Technologies SA | 2023-08-01 | 2,000 | 2.98 | 5,960 |
| ACGN | Aceragen Inc | 2021-03-05 | 1,697 | 0.38 | 645 |
Holding Weightings of Daniel B Soland
Daniel B Soland Form 4 Trading Tracker
According to the SEC Form 4 filings, Daniel B Soland has made a total of 0 transactions in ACADIA Pharmaceuticals Inc (ACAD) over the past 5 years. The most-recent trade in ACADIA Pharmaceuticals Inc is the acquisition of 10,000 shares on March 2, 2018, which cost Daniel B Soland around $234,900.
According to the SEC Form 4 filings, Daniel B Soland has made a total of 0 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years. The most-recent trade in KalVista Pharmaceuticals Inc is the acquisition of 10,000 shares on September 27, 2019, which cost Daniel B Soland around $118,700.
According to the SEC Form 4 filings, Daniel B Soland has made a total of 1 transactions in DBV Technologies SA (DBVT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in DBV Technologies SA is the acquisition of 1,500 shares on August 1, 2023, which cost Daniel B Soland around $24,300.
More details on Daniel B Soland's insider transactions can be found in the Insider Trading History of Daniel B Soland table.Insider Trading History of Daniel B Soland
- 1
Daniel B Soland Trading Performance
GuruFocus tracks the stock performance after each of Daniel B Soland's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Daniel B Soland is -22.38%. GuruFocus also compares Daniel B Soland's trading performance to market benchmark return within the same time period. The performance of stocks bought by Daniel B Soland within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Daniel B Soland's insider trading performs compared to the benchmark.
Performance of Daniel B Soland
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -21.37 | | | | | |
| Relative Return to S&P 500(%) | -22.07 | | | | | |
Daniel B Soland Ownership Network
Daniel B Soland Owned Company Details
What does KalVista Pharmaceuticals Inc do?
Who are the key executives at KalVista Pharmaceuticals Inc?
Daniel B Soland is the director of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include CFO and Secretary Benjamin L Palleiko , Chief Medical Officer Paul K. Audhya , and Chief Development Officer Christopher Yea .
KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary
Over the past 18 months, Daniel B Soland made no insider transaction in KalVista Pharmaceuticals Inc (KALV). Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net sale of 162,750 shares made by Benjamin L Palleiko , a net purchase of 1,251,017 shares made by Venrock Healthcare Capital Partners Iii, L.p. , and a net sale of 95,977 shares made by Christopher Yea .
In summary, during the past 3 months, insiders sold 41,446 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 41,446 shares. During the past 18 months, 607,982 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 643,035 shares.
KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.
KalVista Pharmaceuticals Inc Insider Transactions
Daniel B Soland Mailing Address
Above is the net worth, insider trading, and ownership report for Daniel B Soland. You might contact Daniel B Soland via mailing address: 4560 Horton Street,m/s R-422, Emeryville Ca 94608.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
